Non-Muscle Invasive Urothelial Carcinoma

How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?
Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, shares how sasanlimab has shown a favorable toxicity profile in phase 1 data, which subsequently has led to a phase 3 trial combining the immune checkpoint inhibitor with bacillus Calmette-Guérin (BCG) concurrently in patients with high-risk, BCG-naïve non-muscle invasive bladder cancer (NMIBC). ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Advertisement
Trending